Last updated: February 16, 2026
Overview of the Drug
NDC 51407-0011 corresponds to the drug Baricitinib, marketed under the brand name Olumiant. Approved by the FDA in 2018 for rheumatoid arthritis, it has received Emergency Use Authorization (EUA) for COVID-19 treatment in certain populations. The drug is a Janus kinase (JAK) inhibitor, targeting inflammatory pathways.
Market Landscape
The rheumatoid arthritis (RA) segment dominates the current market for Baricitinib, with COVID-19 indications representing a niche market. The RA market is mature with substantial competition, primarily from drugs like methotrexate, adalimumab, and tofacitinib.
COVID-19 Market: The EUA granted in 2020 was a market driver, but demand diminished as vaccines and other therapeutics gained prominence. As of 2023, COVID-19 usage is limited and subject to regulatory review, reducing potential revenue in this segment.
Market Drivers and Barriers
-
Drivers:
- Increasing prevalence of RA globally, estimated at 0.5%-1% of the population.
- Growing acceptance of targeted JAK inhibitors.
- Expanding off-label uses in autoimmune and inflammatory diseases.
-
Barriers:
- Pricing pressure from biosimilars and generics.
- Penetration of other JAK inhibitors like tofacitinib and upadacitinib.
- Regulatory uncertainty on COVID-19 indications.
Pricing Trends
Current list prices vary by indication, formulation, and regional markets. In the U.S.:
-
Rheumatoid arthritis: The wholesale acquisition cost (WAC) is approximately $5,600 to $6,300 per month based on dosage and packaging, as per SSR Health data (2023).
-
COVID-19 EUA: The federal government initially purchased doses at roughly $2,500 per treatment course; however, these are limited and not commercially available.
Internationally, prices fluctuate:
| Region |
Estimated Monthly Price |
Notes |
| United States |
$5,600 – $6,300 |
Based on current WAC for RA indications |
| European Union |
€4,500 – €5,200 |
Approximate, varies by country |
| Japan |
¥700,000 – ¥850,000 |
Higher pricing due to healthcare system |
Projected Market Growth
The RA segment for JAK inhibitors is projected to grow at a CAGR of 8–10% through 2028, driven by new formulations and expanded indications. The COVID-19 market is expected to contract or plateau as vaccines and alternative therapies dominate.
2023 Estimates:
- Global RA market volume: Approximately 1.2 million patients.
- Unit sales: Estimated at 200,000–250,000 units annually for Baricitinib, considering dosing frequency and indications.
- Revenue: Around $1.2 billion globally from RA indications.
Future Outlook:
Price erosion due to biosimilars is anticipated. Pfizer's Xeljanz (tofacitinib) and AbbVie's Rinvoq (upadacitinib) compete in similar spaces, pressuring prices. Price projections suggest a downward trend of 3–5% annually for existing formulations.
Pricing Strategies and Entry Barriers
- Patent protections: Extended until 2030 in key markets, limiting biosimilar competition.
- Reimbursement policies: Favor innovative therapies for RA; however, price caps may limit revenue growth.
- Market access: High drug costs limit use in some healthcare systems, influencing overall sales.
Regulatory and Market Access Considerations
- Patents and exclusivity: Patents expiring in 2029–2030 in major markets.
- Reimbursement landscape: Varies by country; in the U.S., insurance coverage facilitates access.
- Off-label use: Limited but expanding opportunities.
Summary of Price Projections (Next 5 Years)
| Year |
Estimated Price Range (Monthly) |
Notes |
| 2023 |
$5,600 – $6,300 |
Current market price |
| 2024 |
$5,400 – $6,000 |
Slight erosion due to biosimilar threat |
| 2025 |
$5,200 – $5,800 |
Continued price decline |
| 2026 |
$5,000 – $5,600 |
Competitive pressures increase |
| 2027 |
$4,800 – $5,400 |
Biosimilar emergence starts impacting |
Key Takeaways
- The primary market driver is the RA segment, with robust growth projected but declining prices due to biosimilar competition and patent expiry.
- COVID-19 sales were temporary and are unlikely to be a significant revenue contributor long term.
- Current prices in the U.S. range from approximately $5,600 to $6,300 per month; international prices vary.
- Biosimilar competition and patent expiration forecast a price decline of approximately 3–5% annually over the next five years.
- Industry players should monitor patent timelines, manufacturing costs, and reimbursement policies for strategic positioning.
FAQs
1. What factors influence the pricing of NDC 51407-0011?
Pricing is affected by patent status, manufacturing costs, competitive landscape (biosimilars), regional reimbursement policies, and drug indications.
2. How does biosimilar entry affect price projections?
Biosimilar competition typically drives down prices, with erosion rates of 3–5% annually once biosimilars gain market share, expected post-2025.
3. Are there any upcoming patent expirations for Baricitinib?
Patents in key markets like the U.S. expire around 2029–2030, opening the market to biosunnable competitors and generics.
4. What drives demand for Baricitinib in rheumatoid arthritis?
The drug's targeted mechanism offers advantages over older therapies, especially for patients refractory to traditional DMARDs, bolstered by the growth of biologic and targeted synthetic DMARDs.
5. How significant is the COVID-19 indication for the overall market?
COVID-19 use was temporary, highly restricted, and unlikely to influence long-term revenue significantly. The focus remains on RA and autoimmune indications.
References
[1] SSR Health. (2023). Price and Sales Data for Baricitinib.
[2] IQVIA. (2023). Rheumatoid Arthritis Market Overview.
[3] U.S. FDA. (2018). Approval Documents for Olumiant (Baricitinib).
[4] EvaluatePharma. (2023). Biologic and Small Molecule Trends in Autoimmune Disease.
